Galidesivir
Galidesivir (BCX4430), an adenosine analog originally developed for human coronavirus (HCV), is currently undergoing early-stage clinical studies examining its protection in healthy subjects and its effectiveness against yellow fever, and has demonstrated antiviral activity in preclinical studies against many RNA viruses, like SARS and MERS2, and possibilities are that facilities with sufficient bio-containment capabilities may screen Galidesivir against 2019-nCoV and ongoing human pharmacokinetics will be available after its clinical trial [13] [15] [37].